Eli Lilly and Company announced on May 6 a fresh $4.5 billion investment across its Lebanon manufacturing sites, marking another major step in the company’s push to expand U.S.-based production. This commitment brings Lilly’s total capital investments in Indiana since 2020 to more than $21 billion. It coincides with the opening of Lilly Lebanon Advanced Therapies, the company’s first facility dedicated entirely to genetic medicines.
The additional funding will support upgrades at two of the three planned sites in Lebanon. These include new process designs and technologies for active pharmaceutical ingredient production at Lilly Lebanon API, set to open in 2027, and expanded capabilities at the newly operational Advanced Therapies plant. Company officials cited growing demand for its medicines and an evolving pipeline as the main drivers behind the expansion.
Lilly has positioned Lebanon as a key hub in its domestic manufacturing strategy. The Advanced Therapies facility will handle everything from early research to large-scale commercial supply of genetic medicines. These therapies aim to treat diseases by targeting them at the genetic level, a frontier that requires entirely new manufacturing approaches without much established precedent.
“This expansion reflects the strength of a long-standing partnership between Lilly and the state of Indiana,” Governor Mike Braun said in a statement. “With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing.”
The timing aligns with strong performance from Lilly’s blockbuster products. The Lebanon API site will help produce Zepbound and Mounjaro, the widely prescribed tirzepatide injections for weight management and type 2 diabetes. It will also support Foundayo, Lilly’s recently approved once-daily oral weight-loss pill, and retatrutide, an investigational triple-hormone candidate in late-stage trials for obesity and related conditions.
David A. Ricks, Lilly’s chair and CEO, highlighted the company’s roots in the state. “Lilly’s legacy of firsts in Indiana continues today,” he said. “When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home.”
Beyond direct jobs at the facilities, the economic ripple effects are significant. A forthcoming report from Indiana University’s Kelley School of Business notes that Lilly accounts for about 70 percent of the state’s pharmaceutical GDP. Each Lilly job supports more than two additional positions elsewhere in Indiana, and every dollar spent locally can generate up to four dollars in broader economic activity.
This latest announcement adds to Lilly’s broader U.S. manufacturing push. The company has committed more than $50 billion nationwide since 2020, enabled in part by policies encouraging domestic production. Several new sites are expected to break ground this year.
For the city of Lebanon, the growth represents a long-term boost. Mayor Matt Gentry called the investment “a milestone” that underscores the strength of the local workforce and positions the community as a leader in pharmaceuticals for years to come.
With demand for new therapies rising, Lilly’s significant bet on Indiana manufacturing reflects a simple approach: build in the U.S. to meet global needs while also supporting local economies. The progress in Lebanon could be a model for how targeted investments produce both medical breakthroughs and regional wealth.
